低剂量衰减校正CT诊断非酒精性脂肪性肝病的准确性
研究纳入864例2011年5月至2014年4月间接受临床指征混合核医学扫描的患者,以非增强CT为金标准,评估低剂量CT衰减校正诊断非酒精性脂肪性肝病的准确性;低剂量CTAC在同时满足肝衰减<40 HU和肝脾比<1.1时敏感度81.3%、特异度94.0%、阳性预测值60.2%、阴性预测值97.8%。
要点
- 低剂量CTAC诊断脂肪肝的敏感度81.3%、特异度94.0%、阴性预测值97.8%(同时采用两项标准)。
- 若肝衰减≥40 HU且肝脾比≥1.1,低剂量CT可排除脂肪肝。
- 低剂量CTAC诊断脂肪肝的患病率12.9%(同时采用两项标准)或34.9%(采用任一标准)。
核心结论
- 若肝衰减不低于40 HU且肝脾比不低于1.1,低剂量CT可用于排除脂肪肝。
研究设计与样本
- 回顾性分析864例接受临床指征混合核医学扫描的患者,以非增强CT为金标准,评估低剂量CT衰减校正诊断非酒精性脂肪性肝病的准确性。
诊断标准与关键数值
- 脂肪肝诊断标准为肝绝对衰减<40 HU和/或肝脾比<1.1;低剂量CTAC同时采用两项标准时敏感度81.3%、特异度94.0%、阳性预测值60.2%、阴性预测值97.8%,采用任一标准时敏感度76.8%、特异度83.5%、阳性预测值66.3%、阴性预测值89.5%。
临床应用与阅片要点
- 低剂量CTAC可用于排除脂肪肝:若肝衰减不低于40 HU且肝脾比不低于1.1,则不支持脂肪肝。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Non-enhanced computed tomography (CT) is a valuable modality in the diagnosis of non-alcoholic fatty liver disease (NAFLD). However, it is not clear if low-dose CT attenuation correction (CTAC) scans have the same accuracy to diagnose NAFLD. Our aim is to evaluate the diagnostic accuracy of low-dose CTAC in the diagnosis of NAFLD using non-enhanced CT as a gold standard.
METHODS: A total of 864 patients who underwent a clinically indicated hybrid nuclear imaging scanning between May 2011 and April 2014 were included in the study. Diagnosis of fatty liver was established if an absolute liver attenuation was <40 Hounsfield units and/or a liver-to-spleen ratio was <1.1. The diagnostic accuracy parameters were calculated to detect NAFLD by low-dose CTAC using unenhanced CT as a gold standard.
RESULTS: The prevalence of fatty liver by diagnostic CT and low-dose attenuation correction were 9.9 and 12.9% (using liver attenuation <40HU and liver-to-spleen ratio <1.1), respectively, with 32.9 and 34.9% (using absolute liver attenuation or ratio-to-spleen criteria), correspondingly. Low-dose CTAC had sensitivity (81.3%), specificity (94.0%), positive predictive value (60.2%), and negative predictive value (97.8%) using both diagnostic criteria. Using either of the diagnostic criteria resulted in sensitivity (76.8%), specificity (83.5%), PPV (66.3%), and NPV (89.5%).
CONCLUSION: Low-dose CT could be used as a tool to rule out the presence of fatty liver if neither liver attenuation of less than 40 HU nor liver-to-spleen below 1.1 is present.
引用
- Ahmed AM, Ebid ME, Ajlan AM, et al. Low-dose attenuation correction in diagnosis of non-alcoholic fatty liver disease. Abdom Radiol (NY). 2017. PMID: 28470401. doi:10.1007/s00261-017-1166-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。